Literature DB >> 17606471

Benzylpiperazine: a drug of abuse?

Alice C Johnstone1, Rod A Lea, Katie A Brennan, Susan Schenk, Martin A Kennedy, Paul S Fitzmaurice.   

Abstract

N-benzylpiperazine (BZP) is the active ingredient in recreational 'party' or 'p.e.p.' pills, which are used to provide a stimulant, euphoric effect akin to that of methylenedioxymethamphetamine (MDMA, 'ecstasy'). BZP predominantly affects dopamine neurotransmission in a similar fashion to known 'drugs of abuse', such as methamphetamine and cocaine, which strongly suggests BZP has abuse liability. BZP is illegal in many countries including the United States of America and Australia, yet it remains legal in the United Kingdom, Canada and New Zealand. There has been little research, to date, on the neurological consequences of high dose or chronic exposure of BZP. Here we provide a comprehensive review of the information currently available on BZP and suggest a need for further research into the mechanisms of action, long-term effects and potentially addictive properties of BZP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606471     DOI: 10.1177/0269881107077260

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  5 in total

1.  Pharmacologic neuroimaging of the ontogeny of dopamine receptor function.

Authors:  Y Iris Chen; Ji-Kyung Choi; Haibo Xu; Jiaqian Ren; Susan L Andersen; Bruce G Jenkins
Journal:  Dev Neurosci       Date:  2010-06-03       Impact factor: 2.984

2.  Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users.

Authors:  Tibor M Brunt; Maarten W Koeter; Raymond J M Niesink; Wim van den Brink
Journal:  Psychopharmacology (Berl)       Date:  2011-10-13       Impact factor: 4.530

3.  Determining the subjective and physiological effects of BZP combined with TFMPP in human males.

Authors:  Joanne C Lin; Reem K Jan; HeeSeung Lee; Maree-Ann Jensen; Rob R Kydd; Bruce R Russell
Journal:  Psychopharmacology (Berl)       Date:  2011-04       Impact factor: 4.530

Review 4.  Nephrotoxic effects of common and emerging drugs of abuse.

Authors:  William F Pendergraft; Leal C Herlitz; Denyse Thornley-Brown; Mitchell Rosner; John L Niles
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-17       Impact factor: 8.237

5.  Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis.

Authors:  Laurie S Anderson; Heidi G Bell; Michael Gilbert; Julie E Davidson; Christina Winter; Monica J Barratt; Beta Win; Jeffery L Painter; Christopher Menone; Jonathan Sayegh; Nabarun Dasgupta
Journal:  JMIR Public Health Surveill       Date:  2017-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.